Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study

Core Viewpoint - NetraMark Holdings Inc. has signed a contract with Asklepion Pharmaceuticals to utilize its NetraAI platform for analyzing data from a pivotal Phase III pediatric clinical trial focused on intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects [1][2]. Group 1: Company Overview - NetraMark is a leader in developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry [5]. - The company's technology employs a novel topology-based algorithm that can parse patient data into related subsets, allowing for accurate disease segmentation and patient classification regarding drug sensitivity and treatment efficacy [5]. Group 2: Partnership Details - The agreement with Asklepion aims to enhance the ability to demonstrate the benefits of L-citrulline in specific patient subgroups through the application of NetraAI's advanced AI technology [2][3]. - NetraMark's analysis will focus on identifying responder personas, which are subpopulations of patients most likely to benefit from the treatment, thereby informing future study designs for L-citrulline development [4]. Group 3: Strategic Importance - Asklepion's engagement with NetraMark reflects a commitment to innovation in trial design, aiming to uncover meaningful insights that can optimize patient selection and improve study outcomes [4]. - The integration of NetraAI's explainable AI analytics into Asklepion's late-phase study is expected to sharpen the understanding of L-citrulline and accelerate the development of safer, more effective treatments for children [4].